MBX Biosciences closed at $52.48 on Nov 4, down 4.58%, 25.8% below its 52-week closing high. Volume of 425.5K shares was 0.75× its 20-day average (below normal).
Split-adjusted performance: -7.8% over one month, +63.4% over six months, +154.6% over one year.
Short interest was 4.4M shares at the Oct 15 settlement (15.0% of float, 7.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MBXMBX Biosciences | $52.48 | −4.58% | +63.4% | — | — | — | $2.53B | |
| PBHPrestige Consumer Healthcare | $53.28 | +7.55% | −1.9% | +6.5% | 11.0% | 14.7 | $2.52B | Compare |
| NAMSNewAmsterdam Pharma Company N.V | $20.93 | +5.18% | −32.5% | −80.7% | −1732.9% | — | $2.50B | Compare |
| RCUSArcus Biosciences | $19.31 | +2.12% | −25.7% | −74.4% | −222.0% | — | $2.46B | Compare |
| XNCRXencor | $35.03 | +14.33% | +169.3% | +17.5% | −42.4% | — | $2.60B | Compare |
| PVLAPalvella Therapeutics | $162.28 | +6.11% | +24.7% | — | — | — | $2.34B | Compare |
| VERAVera Therapeutics | $31.97 | +4.10% | −12.6% | — | — | — | $2.30B | Compare |
| IMNMImmunome | $19.52 | −3.89% | −16.1% | −100.0% | — | — | $2.30B | Compare |
| BHVNBiohaven | $15.24 | −2.37% | +51.8% | — | — | — | $2.30B | Compare |
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
